l General Information |
Product Name | Amifostine |
General description | Amifostine is the first approved radioprotective drug, used to decrease the risk of kidney problems caused by treatment with cisplatin. |
Synonym | 2-(3-aminopropylamino)ethylsulfanylphosphonic acid; trihydrate |
Purity | ≥97.0%(T) | CAS Number | 112901-68-5 |
Formula | C5H21N2O6PS | Molecular Weight | 268.265 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Solid |
Solubility(25°C) | DMSO | Very slightly soluble |
Water | ≥35mg/ml |
l Biological Information |
Biochem/Physiol
Actions | Amifostine is the trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues. |
Application | Radiation-Protective Agents |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
